Oncolys aims to contribute to the advancement of medical science, by bringing innovation to the existing treatments for “cancer” and “serious infectious diseases”, leveraging our virology-based new drug discovery technologies.
Especially in the oncology area, Oncolys develops Telomelysin (OBP-301) and OBP-702, oncolytic viral immunotherapy, based on the concept of "cure without surgery".
Oncolys will continuously enrich our pipeline for the treatment of cancer and serious virus infection having significant unmet medical needs.

Progress chart of pipeline (As of June 29th, 2023)